Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19453195 | 0.88 | PTGS1 (0.45) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL576169 | 0.78 | — | — | |
| SCHEMBL28628438 | 0.78 | PTGS1 (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2854813 | 0.76 | PTGS1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL4817810 | 0.73 | — | — | |
| SCHEMBL18222457 | 0.72 | PTGS1 (0.33) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28944875 | 0.72 | PTGS1 (0.33) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL31298340 | 0.71 | PTGS1 (0.32) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL31298343 | 0.71 | PTGS1 (0.32) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL210531 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260058199-A1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | SUMITOMO SEIKA CHEMICALS (JP) | 2026-02-26 | — | — | US | disclosed |
| EP-4546488-A1 | SECONDARY BATTERY NON-AQUEOUS ELECTROLYTIC SOLUTION, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2025-04-30 | — | — | EP | disclosed |
| EP-4542711-A1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2025-04-23 | — | — | EP | disclosed |
| CN-114243203-B | High-elongation diaphragm, preparation method thereof and lithium ion battery | 远景动力技术(江苏)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-110383565-B | Additive for nonaqueous electrolyte solution, and electricity storage device | 住友精化株式会社 | 2022-08-23 | — | — | CN | disclosed |
| US-11387490-B2 | Additive for nonaqueous electrolyte solutions, nonaqueous electrolyte solution, and electricity storage device | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20180287146-A1 | LITHIUM POWDER, LITHIUM ION SECONDARY BATTERY NEGATIVE ELECTRODE USING THE SAME, AND LITHIUM ION SECONDARY BATTERY USING THE LITHIUM ION SECONDARY BATTERY NEGATIVE ELECTRODE | TDK CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260058199-A1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | KCNN2, KCNN1, SLC9A1 | PTGS1 4720/4885PDE4A 3114/4885LMNA 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.